Table 1.
Demographic differences between sub-groups at study entry.
| Non-converters | Converters | Freezers | P1,2 | P3 | P3 | P3 | |
|---|---|---|---|---|---|---|---|
| Non-converters – Converters | Non-converters – Freezers | Converters – Freezers | |||||
| N | 36 | 9 | 12 | ||||
| Age | 59 (14.3) | 57 (17.5) | 69 (11.5) | 0.107 | |||
| Gender (F) | 7 (47.2%) | 4 (44 %) | 1 (8.3%) | 0.052 | |||
| Disease Duration (Years) | 5 (5.1) | 7 (5.5) | 7.5 (3.8) | 0.021 | 0.036 | ||
| LEDD | 412.5 (313) | 814 (452) | 639 (311) | 0.032 | .050 | ||
| MDS-UPDRS Part I | 9 (4) | 15 (11) | 9 (8.3) | 0.046 | .042 | ||
| MDS-UPDRS Part II | 8.5 (6.8) | 10 (12) | 16.5 (14.8) | <0.001 | <0.001 | ||
| MDS-UPDRS Part III | 23.5 (14.3) | 30 (10.5) | 39 (12.5) | 0.001 | 0.001 | ||
| MDS-UPDRS Part IV | 1 (3.5) | 2 (4.5) | 0 (2) | 0.291 | |||
| MDS-UPDRS Total | 43.5 (21) | 62 (22.5) | 70.5 (33.3) | <0.001 | .015 | < .001 | |
| Hoehn & Yahr (I / II / III) | 9/21/6 | 0/7/1 | 0/9/2 | 0.062 | |||
| MOCA (0–30) | 27 (3) | 28 (3.5) | 25.5 (4.8) | 0.434 | |||
| FAB (0–18) | 16 (1.8) | 16 (2.5) | 15 (3) | 0.045 | |||
| Trail Making Test B-A (s) | 38.3 (30) | 41.7 (39.6) | 52 (65) | 0.302 | |||
| Alternate Naming Test (s) | 21 (11.6) | 14.1 (11.5) | 26 (24.7) | 0.033 | 0.045 | ||
| Figure of Rey Copy (s) | 102 (48) | 80 (38.7) | 115.5 (96.2) | 0.256 | |||
| Figure of Rey Recall | 21 (13.5) | 23.5 (7.5) | 22 (14) | 0.438 | |||
| HADS Anxiety (0–21) | 6 (7.5) | 6 (9.5) | 6 (3.8) | 0.889 | |||
| HADS Depression (0–21) | 4.5 (4.8) | 6 (4) | 6 (6.5) | 0.193 | |||
| Fallers | 4 (11%) | 4 (44%) | 6 (50%) | 0.009 | 0.021 | ||
| MiniBEST score (0–28) | 25 (4) | 26 (2) | 22 (6.8) | 0.002 | 0.004 | 0.005 |
Group median values (interquartile range) or number (percentage) along with p-values reported. 1: One-way ANOVA with Group as Main Effect for scale measures, 2: χ2 Likelihood Ratio for class measures, 3: Bonferroni corrected post-hoc pairwise tests. LEDD Daily Levodopa Equivalent Dose, Non-LED Non Levodopa medication usage, MDS-UPDRS Movement Disorder Society sponsored revision of the Unified Parkinson’s Disease Rating Scale, MOCA Montreal Cognitive Assessment, FAB Frontal Assessment Battery, HADS Hospital Anxiety and Depression Scale, MiniBEST Mini Balance Evaluation Systems Test. Note: All non-converters and converters were non-freezers at study entry. Sub-group assignments were based on FOG classification at study exit.